Neurology News

High regular physical activity levels and exercise habits over time appeared significantly correlated with better outcomes in Parkinson’s disease, according to results of an observational cohort study published in Neurology.

Epstein-Barr virus infection, which causes mononucleosis, may represent a primary cause of MS, according to results of a longitudinal analysis published in Science.

Clinical-stage biotech developer ABL Bio Inc. announced it will collaborate and enter a worldwide license agreement with Sanofi to develop and commercialize a treatment for Parkinson’s disease and other potential indications.

Roche is designing a new phase 2 trial to examine tominersen in Huntington’s disease, according to a press release from Roche’s partner, Ionis Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. and Stoke Therapeutics Inc. announced they will collaborate to develop novel RNA-based medicines as potential treatments for severe and rare genetic neurodevelopmental central nervous system diseases.

PharmaTher Holdings Ltd., a specialty ketamine prescription-based product development company, announced the FDA has accepted an investigational new drug application for proceeding with a phase 2 clinical trial to examine ketamine for ALS.

Researchers observed no independent association between chronic kidney disease and pre- or post-event dementia among patients with transient ischemic attack and stroke, according to results of a population-based cohort study.

The American Academy of Neurology has issued a position statement for neurologists that outlines ethical guidance on issues related to consent for individuals with acute ischemic stroke.

Both at the end of the year and in the beginning of the following year, many physicians focus on charitable planning.

Greater prevalence and severity of head injuries as one’s life span continues shows a correlation to an increased risk for late-onset epilepsy, according to a cohort study published in Neurology.